Sacubitril/Valsartan Versus Enalapril in Chronic Chagas Cardiomyopathy: Rationale and Design of the PARACHUTE-HF...

Area of Science:

• Cardiology
• Tropical Medicine
• Clinical Trials

Background:

• Chronic Chagas cardiomyopathy (CCC) presents unique challenges in heart failure (HF) management, often affecting younger patients with fewer comorbidities but having a worse prognosis.
• Current HF treatment guidelines lack adequate representation of CCC patients, necessitating specific research.
• The PARACHUTE-HF trial addresses this gap by focusing on a high-risk population often overlooked in major cardiovascular studies.

Purpose of the Study:

• To evaluate the efficacy and safety of sacubitril/valsartan compared to enalapril in patients with Chronic Chagas cardiomyopathy and reduced ejection fraction.
• To assess the impact of sacubitril/valsartan on cardiovascular death, HF hospitalization, and NT-proBNP levels in CCC patients.
• To provide crucial data for optimizing HF treatment strategies in the Chagasic population.

Main Methods:

• An active-controlled, randomized, phase IV clinical trial (PARACHUTE-HF).
• Enrollment of approximately 900 patients with CCC and reduced ejection fraction across ~100 sites in Latin America.
• Comparison of sacubitril/valsartan 200 mg twice daily versus enalapril 10 mg twice daily, both added to standard HF care.

Main Results:

• The primary outcome is a hierarchical composite assessing time to cardiovascular death, first HF hospitalization, or relative change in NT-proBNP levels at 12 weeks.
• The study will yield new data on morbidity and mortality in CCC patients treated with guideline-directed medical therapy.
• Analysis will focus on the comparative effectiveness of novel therapy (sacubitril/valsartan) against an established agent (enalapril).

Conclusions:

• PARACHUTE-HF is expected to provide critical insights into the management of heart failure in Chronic Chagas cardiomyopathy.
• Findings will inform treatment guidelines and clinical practice for this specific, high-risk patient group.
• The trial aims to establish optimal therapeutic strategies to improve prognosis and reduce adverse events in CCC patients.